These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 31984118)

  • 21. Conventional TACE and drug-eluting bead TACE as locoregional therapy before orthotopic liver transplantation: comparison of explant pathologic response.
    Frenette CT; Osorio RC; Stark J; Fok B; Boktour MR; Guy J; Rhee J; Osorio RW
    Transplantation; 2014 Oct; 98(7):781-7. PubMed ID: 24825513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immediate post-doxorubicin drug-eluting beads chemoembolization Mr Apparent diffusion coefficient quantification predicts response in unresectable hepatocellular carcinoma: A pilot study.
    Kokabi N; Camacho JC; Xing M; Edalat F; Mittal PK; Kim HS
    J Magn Reson Imaging; 2015 Oct; 42(4):981-9. PubMed ID: 25683022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent Diffusion Coefficient as a Noninvasive Biomarker for the Early Response in Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization Using Drug-eluting Beads.
    Li B; Zhou L; Xu A; Li Q; Xiang H; Huang Y; Peng L; Xiang K; Zhang M; Wang N
    Curr Med Imaging; 2022; 18(11):1186-1194. PubMed ID: 35249499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve.
    Fidelman N; Johanson C; Kohi MP; Kolli KP; Kohlbrenner RM; Lehrman ED; Taylor AG; Kelley RK; Yao FY; Roberts JP; Kerlan RK
    J Hepatocell Carcinoma; 2019; 6():93-103. PubMed ID: 31355158
    [No Abstract]   [Full Text] [Related]  

  • 26. Occurrence, Related Factors and Prognostic Value of Vascular Lake in Hepatocellular Carcinoma Patients Treated with Drug-Eluting Bead Transarterial Chemoembolization.
    Li H; Wang M; Chen P; Li F; Kuang D; Han X; Ren J; Duan X
    Onco Targets Ther; 2021; 14():4659-4670. PubMed ID: 34511935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
    Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-eluting bead transarterial chemoembolization could improve the hepatic hemodynamics of patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Wang T; Du YN; Sun J; Song H; Jiang Y; Liu F; Lv X
    J Gastrointest Oncol; 2023 Feb; 14(1):302-311. PubMed ID: 36915464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
    Ludwig JM; Zhang D; Xing M; Kim HS
    Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma: The Effectiveness of Different Particle Sizes in Downstaging and Bridging in Living Donor Liver Transplantation.
    Lim WX; Sim KS; Chen CL; Ou HY; Yu CY; Cheng YF
    Transplant Proc; 2024 Apr; 56(3):596-601. PubMed ID: 38472083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Radiological appearance of hepatocellular carcinoma predicts the response to trans-arterial chemoembolization in patients undergoing liver transplantation.
    Zhang W; Xu AH; Wang W; Wu YH; Sun QL; Shu C
    BMC Cancer; 2019 Nov; 19(1):1041. PubMed ID: 31690274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 38. Conventional
    Song JE; Kim DY
    World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
    Shiozawa K; Watanabe M; Ikehara T; Ogino Y; Umakoshi T; Matsukiyo Y; Kogame M; Matsui T; Kikuchi Y; Igarashi Y; Sumino Y
    Case Rep Oncol; 2014 Sep; 7(3):739-45. PubMed ID: 25520649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE).
    Fronda M; Mistretta F; Calandri M; Ciferri F; Nardelli F; Bergamasco L; Fonio P; Doriguzzi Breatta A
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.